In November 2010, LLS made an equity investment in Biotheryx originally to support the development of a promising LLS-funded project with Toronto-based University Health Network. Biotheryx is currently enrolling "An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects With Advanced Malignancies."
Biotheryx is a clinical stage biopharmaceutical company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs) in areas of high unmet medical need, with an initial focus on cancer. TPD technology utilizes the body's own protein disposal system to selectively degrade and remove disease-causing proteins. It has potential applicability to a very broad range of disease targets, including a wide range of targets that have to date been considered "undruggable." A clinical study of BXT-1188, oral, dual target protein degrader specifically engineered to degrade GSPT1 and IKZF1/3, in patients with advanced hematologic and solid tumor malignancies is currently enrolling (NCT05144334).
For more information about Biotheryx, visit www.biotheryx.com.
- May 26, 2022 - announced supportive preclinical data for its lead asset BTX-1188, a potentially first-in-class, dual protein degrader of GSPT1 and IKZF1/3, will be presented in a poster at the 2022 ASCO) Annual Meeting taking place June 3-7, 2022
- January 26, 2022 - announced dosing of the first patient in a new, first-in human Phase 1 study investigating its lead candidate BTX-1188, an oral, dual target protein degrader specifically engineered to degrade GSPT1 and IKZF1/3, in patients with advanced hematologic and solid tumor malignancies.
- November 2, 2021 - announced that the U.S. FDA cleared the company to proceed with a Phase 1 clinical trial of BTX-1188 in hematologic and solid malignancies. BTX-1188 is a novel oral small molecule cereblon binder that has immunomodulatory properties and promotes the degradation of GSPT1, a translation termination factor, as well as IKZF1/3, zinc finger transcription factors. Enrollment for the phase 1 clinical trial is expected to commence by end of 2021.
- May 20, 2021 - announced a $92 million Series E financing led by Farallon Capital Management, with participation from additional new investors and existing investors. The proceeds from the financing will be used to advance multiple molecular glues, PHM-based PROTACs and monovalent degraders for the treatment of acute myeloid leukemia, myelodysplastic syndromes and solid tumors.